Skip to main content

Increasing Prevalence of Osteoarthritis to Augment the Viscosupplementation Market Growth

 


Viscosupplementation is a minimally invasive procedure that helps reduce joint pain and improves the functional condition of the osteoarthritic joint. It is a treatment in which a thick fluid named hyaluronate or hyaluronic acid is injected into the knee joint Hyaluronic acid is distributed throughout the body in epithelial, connective tissues, and neural tissues to promote better joint development and lubrication. Osteoarthritis is a type of arthritis that occurs when the flexible tissue at the ends of bones begins to wear down. Moreover, osteoarthritis is the most common form of arthritis in the world. It can be classified into 2 categories such as primary and secondary osteoarthritis.

Osteoarthritis is characterized by loss of function and degeneration of cartilage and tissues that cover the ends of the bones in a joint. There is not a complete cure for osteoarthritis, hyaluronic acid is thought to improve the lubricating properties of the synovial fluid, provide a more comfortable level of activity, improve mobility, and reduce the pain from osteoarthritis of the knee. The increasing prevalence of osteoarthritis is expected to increase the demand for viscosupplementation products, which is expected to drive the viscosupplementation market growth. According to the World Health Organization (WHO), around 9.6% of men and 18.0% of women aged 60 years and above have symptomatic osteoarthritis worldwide. However, the number is expected to increase due to the growing geriatric population and the obesity epidemic.

Moreover, novel biomimetic polymer viscosupplements are rapidly replacing in-development osteoarthritis joint injections, and thus, key players are focused on increasing research and development in biocompatible polymers. These polymers are widely used in the Food and Drug Administration (FDA) approved stents, surgical meshes, and contact lenses, and help prevent degradation associated with hyaluronate. Furthermore, the viscosupplementation market is expected to witness robust growth in 2021 with a somewhat recovery of emerging and developed economies from the global pandemic (COVID-19).

In terms of geography, the market is divided into six regions, such as North America, Europe, Asia Pacific, South America, the Middle East, and Africa. Osteoarthritis is the most common joint disorder in the United States. The increasing prevalence of lifestyle-induced disorders, increasing demand for non-surgical treatments for osteoarthritis, and technological advances in the development of hyaluronic acid-based therapies are some of the factors expected to foster the viscosupplementation market growth. For instance, in 2019, Anika Therapeutics showcased HYALOFAST, a biodegradable, hyaluronic acid-based scaffold for cartilage repair at the 2019 International Cartilage Regeneration and Joint Preservation Society (ICRS) Focus Meeting.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

The Global Pressure Bandages Market Is Witnessing High Growth Owing To the Increasing Incidence of Surgical Processes in the World

  Market Overview: During a medical emergency, a pressure bandage is used to apply pressure to an area of the body to control bleeding and swelling. There are a variety of types of pressure bandages that can be used for different purposes. The bandage is made up of several parts, including an air bladder, a pad, a closure bar, and an applicator. A pressure bandage can be applied to wounds at any location on the body. This type of dressing is useful in treating various conditions, including gunshot wounds. It can also be used for a temporary holding of a hernia. The bandage is usually vacuum-sealed, so it's easier to carry. Competitive Landscape: Major players operating in the global pressure bandages market include ConvaTec Group PLC., Cardinal Health, 3M, B. Braun Melsungen AG, Lohmann & Rauscher GmbH & Co. KG, Mölnlycke Health Care AB, Smith & Nephew plc., Paul Hartmann AG, and Essity (BSN medical GmbH). Key Market Drivers: Increasing developments by key pla...
Post a Comment
Read more

Increasing Incidences of Infectious Diseases to Augment the Antibacterial Drugs Market Growth

  Antibacterial drugs are widely used to treat and prevent infectious diseases and are categorized into seven major classes, such as β-Lactams, phenicols, macrolides, quinolones, sulfonamides, tetracyclines, and aminoglycosides, based on their molecular structure. Antibacterial drugs destroy or slow down the growth of bacteria. These medications are also used to treat urinary infections caused by S. aureus, E. coli, Streptococcus pyogenes, and other bacterial infections. They include a range of powerful drugs used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs. Antibacterial drugs play a major role in advanced healthcare, as they are widely used to treat infectious diseases, such as tuberculosis, malaria, typhoid, leprosy, hepatitis B, HIV/AIDS, and others. Thus, there is an increasing demand for antibacterial drugs worldwide.  
Post a Comment
Read more

Immuno-oncology: Combination Therapies and Emerging Targets

  The study of and creation of therapies that use the immune system of the body to combat cancer are known as immuno-oncology. Our immune system, which is made up of a complex web of organs, cells, and molecules, guards us against external invaders like bacteria, fungus, and viruses that might infect us. The immune system is capable of locating and eliminating foreign objects as well as attacking aberrant cells. The immune system has the best chance of specifically destroying tumours without harming healthy tissue and having long-term memory that can stop cancer from coming back. The development of tumours can be permanently prevented or managed by a mechanism known as immunosurveillance, according to research in immuno-oncology conducted over the past 30 years. Recognition of tumour antigens is what gives the immune response its tumour specificity. The most well-established therapeutic class of IO drugs to date, immune checkpoint inhibitors have demonstrated significant effic...
Post a Comment
Read more